C Zeidler1, S Steinke1, C Riepe1, P Bruland2, I Soto-Rey2, M Storck2, S Garcovich3, C Blome4, S Bobko5, F J Legat6,7, N Potekaev5, A Lvov5, L Misery8, W Weger6, A Reich9, E Şavk10, M Streit11, E Serra-Baldrich12, J C Szepietowski13, G Yosipovitch14, S C Chen9, M Dugas2, S Ständer1. 1. Department of Dermatology and Center for Chronic Pruritus, University Hospital of Münster, Münster, Germany. 2. Institute of Medical Informatics, University of Münster, Münster, Germany. 3. Institute of Dermatology, Policlinico A. Gemelli University Hospital, Catholic University of the Sacred Heart, Rome, Italy. 4. Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg, Hamburg, Germany. 5. Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology, Moscow, Russia. 6. Department of Dermatology, Medical University of Graz, Graz, Austria. 7. Das Kurhaus, Bad Gleichenberg, Austria. 8. Department of Dermatology, University Hospital of Brest, Brest, France. 9. Department of Dermatology, University of Rzeszów, Rzeszów, Poland. 10. Department of Dermatology, Adnan Menderes University, Aydın, Turkey. 11. Department of Dermatology, Kantonsspital Aarau, Aarau, Switzerland. 12. Cutaneous Allergy Unit, Department of Dermatology, Hospital Sant Pau, Universitat Autònoma Barcelona, Barcelona, Spain. 13. Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland. 14. Department of Dermatology and Cutaneous Surgery and Miami Itch Center, Miller School of Medicine, University of Miami, Miami, FL, USA.
Abstract
BACKGROUND: Chronic pruritus (CP) is a frequently occurring symptom in inflammatory dermatoses, causing a high burden and limitations to health-related quality of life (HRQoL). OBJECTIVE: The ItchyQoL was developed to assess the impairment to HRQoL in patients with CP. However, it has only been validated in English and German. Here, we report the validation in several languages across Europe. METHODS: After professional translation, the versions of ItchyQoL were digitized for use as a tablet application. Validation was performed in clinics for dermatology in Austria, France, Germany, Italy, Poland, Russia, Spain, Switzerland and Turkey. RESULTS: Five hundred and thirty-five patients with either contact dermatitis, chronic prurigo - nodular type, psoriasis vulgaris, lichen planus or mycosis fungoides/Sézary syndrome and with CP ≥ 3 on the numerical rating scale were included. ItchyQoL showed a high level of consistency (Cronbach's-α, all: 0.95) and test-retest reliability (intraclass correlation: 0.91). It strongly correlated with the Dermatology Life Quality Index (r = 0.72, P < 0.001) and moderately correlated with itch intensity scales in the study population (visual analogue scale r = 0.46; numerical rating scale r = 0.51; verbal rating scale r = 0.51, for all: P < 0.001). CONCLUSION: ItchyQoL is now also validated in French, Italian, Polish, Russian, Spanish and Turkish and can be used in clinical trials in countries speaking these languages.
BACKGROUND:Chronic pruritus (CP) is a frequently occurring symptom in inflammatory dermatoses, causing a high burden and limitations to health-related quality of life (HRQoL). OBJECTIVE: The ItchyQoL was developed to assess the impairment to HRQoL in patients with CP. However, it has only been validated in English and German. Here, we report the validation in several languages across Europe. METHODS: After professional translation, the versions of ItchyQoL were digitized for use as a tablet application. Validation was performed in clinics for dermatology in Austria, France, Germany, Italy, Poland, Russia, Spain, Switzerland and Turkey. RESULTS: Five hundred and thirty-five patients with either contact dermatitis, chronic prurigo - nodular type, psoriasis vulgaris, lichen planus or mycosis fungoides/Sézary syndrome and with CP ≥ 3 on the numerical rating scale were included. ItchyQoL showed a high level of consistency (Cronbach's-α, all: 0.95) and test-retest reliability (intraclass correlation: 0.91). It strongly correlated with the Dermatology Life Quality Index (r = 0.72, P < 0.001) and moderately correlated with itch intensity scales in the study population (visual analogue scale r = 0.46; numerical rating scale r = 0.51; verbal rating scale r = 0.51, for all: P < 0.001). CONCLUSION: ItchyQoL is now also validated in French, Italian, Polish, Russian, Spanish and Turkish and can be used in clinical trials in countries speaking these languages.
Authors: Hideyuki Ujiie; David Rosmarin; Michael P Schön; Sonja Ständer; Katharina Boch; Martin Metz; Marcus Maurer; Diamant Thaci; Enno Schmidt; Connor Cole; Kyle T Amber; Dario Didona; Michael Hertl; Andreas Recke; Hanna Graßhoff; Alexander Hackel; Anja Schumann; Gabriela Riemekasten; Katja Bieber; Gant Sprow; Joshua Dan; Detlef Zillikens; Tanya Sezin; Angela M Christiano; Kerstin Wolk; Robert Sabat; Khalaf Kridin; Victoria P Werth; Ralf J Ludwig Journal: Front Med (Lausanne) Date: 2022-06-09
Authors: Piotr K Krajewski; Kinga Tyczyńska; Klaudia Bardowska; Piotr Olczyk; Magdalena Krajewska; Jacek C Szepietowski Journal: Toxins (Basel) Date: 2022-04-30 Impact factor: 5.075
Authors: Aleksandra A Stefaniak; Piotr K Krajewski; Dorota Bednarska-Chabowska; Marek Bolanowski; Grzegorz Mazur; Jacek C Szepietowski Journal: Biology (Basel) Date: 2021-12-15